Dr. Reddy's Laboratories
RDY | NYSE
$14.70
-$0.04 (-0.27%)
At close: Nov 16, 2026, 4:00 PM ET
$14.70
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 5:46 PM ET
Dr. Reddy's Laboratories Company Profile
Company profile explainedCompany Profile
Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products. These offerings are available either under a proprietary brand or as generic formulations that are therapeutically identical to their branded equivalents. This segment also includes the company's biologics ventures. The Pharmaceutical Services and Active Ingredients (PSAI) division focuses on producing and distributing active pharmaceutical ingredients (APIs) and chemical intermediates, which serve as crucial building blocks for final drug products. Additionally, PSAI provides contract research services and produces custom-specified APIs and steroids for clients. The Proprietary Products segment is dedicated to the research and advancement of unique pharmaceutical formulations. The Others segment is actively involved in developing treatments, primarily for oncology (cancer) and inflammatory conditions. Dr. Reddy's addresses a broad spectrum of therapeutic areas, including gastrointestinal issues, cardiovascular health, diabetes, dermatological concerns, cancer, respiratory diseases, oral health, urological disorders, and nephrological conditions. The company has also established a partnership with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists designed for immuno-oncology and precision oncology targets. Founded in 1984, Dr. Reddy's Laboratories Limited maintains its principal office in Hyderabad, India.
Key Executives
| Name | Position |
|---|---|
| Deepak Sapra | CEO API and Services & Member of Management Council |
| Erez Israeli | Chief Executive Officer & Member of the Management Council |
| Milan Kalawadia | Chief Executive Officer of North America & Member of Management Council |
| Motupalli Venkata Ramana | CEO of Global Generics & Member of Management Council |
| Mannam Venkatanarasimham | Chief Financial Officer & Member of the Management Council |
| Bhethanabottla S. Phanimitra | Chief Digital and Information Officer & Member of the Management Council |
| Gunupati Venkateswara Prasad | Co-Chairman, MD & Member of Management Council |
| Kallam Satish Reddy | Chairman of the Board & Member of the Management Council |
| Krishna K. Venkatesh B.Pharma | Global Head of IPDO, Integrated Product Development & Member of the Management Council |
| Patrick Aghanian | Head of Consumer Health Organization & Member of Management Council |
| Sanjay Sharma | Executive VP, COO & Member of Management Council |
Dr. Reddy's Laboratories
| Country | India |
| IPO Date | Apr 11, 2001 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 27,527 |
| CEO | Erez Israeli |
Contact Details
8-2-337, Road No. 3 Hyderabad,
TS 500034 India
Stock Details
| Ticker Symbol | RDY |
| Exchange | NYSE |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001135951 |
| CUSIP Number | 256135203 |
| ISIN Number | US2561352038 |
| SIC Code | 2834 |
Recent News
- 22 days ago / zacks.comRDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales Fall
- 22 days ago / fool.comDr. Reddy's Laboratories: 3 Key Takeaways for Long-Term Investors
- 24 days ago / seekingalpha.comDr. Reddy's Laboratories Limited (RDY) Q2 2027 Earnings Call Transcript
- 25 days ago / marketbeat.comDr. Reddy's Laboratories Q2 Earnings Call Highlights
- 2 months ago / reuters.comIndia's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India
- 4 months ago / businesswire.comDr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States
- 4 months ago / youtube.comU.S. pharma tariffs 'can't be absorbed' and drug prices will increase, says Dr Reddy's CEO
- 4 months ago / cnbc.comU.S. to see higher generic drug prices thanks to tariffs, CEO of leading India pharma firm warns
- 4 months ago / gurufocus.comDr Reddy's Laboratories Ltd (RDY) Shares Surge 3.7% -- What GF Score of 83 Tells Investors
- 4 months ago / zacks.comDr. Reddy's Q1 Earnings and Revenues Miss Estimates, Stock Down
Add to Watchlist
Select watchlists to add or remove RDY